Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

Trial profile Fox K et al. Lancet 2008;372:

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Randomized, double-blind, multicenter, controlled trial.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.

Clinical Outcomes with Newer Antihyperglycemic Agents

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:

Baseline Characteristics of Patients Referred for Stress Myocardial Perfusion Testing by Erectile Function Classification James K. Min, et al, Arch Intern.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

R3 JUNG Myounghwa/Prof.KIM Woo-Shik N Engl J Med 2012;366:

Use of Azithromycin and Death from Cardiovascular Causes Whitney Shirley University of Georgia Pharm.D. Candidate 2014.

Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.

Mega JL, et al. N Engl J Med 2009;360: Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.

Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H

Discontinuation of medication after nonfatal event: MI

The SPRINT Research Group

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

LEADER trial: Primary Outcome

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

Baseline Characteristics of the Patients Part I

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

TNT: Baseline and final LDL cholesterol levels

Baseline characteristics of patients

TNT Study: Baseline Characteristics of the Patients

PREMIER: Rate of hypertension at 18 months

Trial profile John A Dormandy et al. Lancet 2005;366:

Study Design Ketil Lunde, et al. N Engl J Med 2006;355:

Fellström BC, et al. N Engl J Med 2009;360:1455-7

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Cystatin C levels and risk of death from all causes

Characteristics of elderly patients prescribed statins after acute myocardial infarction (AMI) in Quebec, Ontario and British Columbia - Part I Zheng.

Enrollment and Outcomes

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Baseline Characteristics of the Subjects

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

Baseline Characteristics of the Study Participants

Women’s Health Study: Baseline Characteristics Part 1

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Baseline Characteristics of the Patients – Part I

Baseline Characteristics of the Patients - Part I

A Single Participant Exposed Twice to an Inflammatory Stimulus

Cardiovascular risk in chronic kidney disease

Comparison of Baseline Characteristics by Primary End Point

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Increase of physical activity over time associated with lower HF risk

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Presentation transcript:

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al, for the CHARISMA Investigators N Engl J Med 2006;354:1706-17

Baseline Characteristics Deepak L.Bhatt, et al, for the CHARISMA Investigators N Engl J Med 2006;354:1706-17

Concomitant Medications* Deepak L.Bhatt, et al, for the CHARISMA Investigators N Engl J Med 2006;354:1706-17

Composite and Individual Primary and Secondary End Points Deepak L.Bhatt, et al, for the CHARISMA Investigators N Engl J Med 2006;354:1706-17

Hazard Ratios for Myocardial Infarction (MI),Stroke, or Death from Cardiovascular Causes in Each of the Subgroups Examined Deepak L.Bhatt, et al, for the CHARISMA Investigators N Engl J Med 2006;354:1706-17